论文部分内容阅读
目的 :研究可溶性细胞间黏附分子 1(solubleintercellularadhesionmolecule 1,sICAM 1)在活动期Graves眼病(Gravesopthalmopathy ,GO)患者治疗前后外周血中的表达 ,探讨sICAM 1在Graves眼病中的作用。方法 :4 2例活动期Graves眼病患者根据伴有或不伴有甲亢分为两组。同时设 2 0正常人为对照组。抽取所有患者激素治疗前后的血液 ,用Elisa方法检测血清中sICAM 1的浓度同正常健康人做对比。结果 :GO患者血清中的sICAM 1浓度显著高于对照组 ,伴甲亢者比不伴甲亢者血清中的sICAM 1浓度高 ,二者同对照组比较差异有显著意义。激素治疗后比治疗前显著降低 ,差异有显著意义 ;但与对照组相比差异无显著性。结论 :sICAM 1参与了Graves眼病的发生 ,其血清浓度同Graves眼病的活动性有关。检测患者血清中的sICAM 1浓度对评估Graves眼病的活动性有一定的临床意义。
Objective: To investigate the expression of sICAM 1 in peripheral blood of active Graves opthalmopathy (GO) patients before and after treatment, and to explore the role of sICAM 1 in Graves ophthalmopathy. Methods: Forty two patients with active Graves ophthalmopathy were divided into two groups according to whether hyperthyroidism or not. At the same time set 20 normal control group. Blood was collected from all patients before and after hormone therapy, and the serum concentration of sICAM 1 was measured by Elisa method in comparison with healthy controls. Results: The serum concentration of sICAM 1 in GO patients was significantly higher than that in control subjects. The serum concentrations of sICAM 1 in patients with hyperthyroidism and those without hyperthyroidism were significantly higher than those in control subjects. After hormone therapy than before treatment significantly reduced, the difference was significant; but compared with the control group no significant difference. Conclusion: sICAM 1 participates in the development of Graves ophthalmopathy, whose serum concentration is related to the activity of Graves ophthalmopathy. Detection of serum sICAM 1 in patients with Graves eye disease assessment of the activity of a certain clinical significance.